ストックスクリーナーアプリを入手
8.11
1.25%
0.10
前日終値:
$8.01
開ける：
$8.01
24時間の取引高:
1.85M
Relative Volume:
1.07
時価総額：
$1.29B
収益：
$61.10M
当期純損益:
$-138.36M
株価収益率:
-6.0074
EPS:
-1.35
ネットキャッシュフロー:
$-90.59M
1週間 パフォーマンス:
+11.10%
1か月 パフォーマンス:
-7.84%
6か月 パフォーマンス:
-16.99%
1年 パフォーマンス:
+42.28%
1日の値動き範囲:
$7.86
$8.2992
1週間の範囲:
$6.86
$8.2992
52週間の値動き範囲:
$4.79
$11.78
Ocular Therapeutix Inc Stock (OCUL) Company Profile
OCUL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
8.11 | 1.11B | 61.10M | -138.36M | -90.59M | -1.35 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-08 | 開始されました | William Blair | Outperform |
| 2025-03-18 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-03-11 | 開始されました | Needham | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-06-20 | アップグレード | TD Cowen | Hold → Buy |
| 2024-05-31 | 再開されました | Piper Sandler | Overweight |
| 2024-02-09 | 開始されました | BofA Securities | Buy |
| 2023-04-21 | 開始されました | Robert W. Baird | Outperform |
| 2022-08-10 | 再開されました | Berenberg | Buy |
| 2021-08-10 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | 開始されました | Berenberg | Buy |
| 2020-11-13 | 繰り返されました | Raymond James | Strong Buy |
| 2020-08-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-03 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | ダウングレード | Cowen | Outperform → Market Perform |
| 2019-05-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-05-21 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2018-11-15 | 開始されました | Raymond James | Strong Buy |
| 2018-09-07 | 開始されました | Piper Jaffray | Overweight |
| 2017-10-24 | 開始されました | Guggenheim | Buy |
| 2017-07-26 | 開始されました | H.C. Wainwright | Buy |
| 2017-07-12 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2017-06-23 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2016-08-11 | 開始されました | JMP Securities | Mkt Outperform |
| 2016-02-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Ocular Therapeutix Inc (OCUL) 最新ニュース
Ocular gains as Wet AMD trial for lead asset reaches enrollment target - MSN
Ocular Therapeutix (OCUL) Maintains "Buy" Rating with $15 Price Target | OCUL Stock News - GuruFocus
Millennium Management LLC Takes $3.82 Million Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock Holdings Lessened by Bank of America Corp DE - Defense World
Demystifying Ocular Therapeutix: Insights From 7 Analyst Reviews - Benzinga
Ocular Therapeutix (OCUL) Advances with Axpaxli Trial Completion - GuruFocus
Ocular Therapeutix (NASDAQ:OCUL) Has Debt But No Earnings; Should You Worry? - simplywall.st
Sector Update: Health Care - marketscreener.com
Ocular Shares Rise After Eye Disease Trial Nears Enrollment Completion - marketscreener.com
Ocular stock gains after wet AMD trial update (OCUL:NASDAQ) - Seeking Alpha
Ocular Therapeutix chief scientific officer sells $21,712 in stock - Investing.com Australia
Ocular Therapeutix (OCUL) Concludes Enrollment for Key Retinal Trial | OCUL Stock News - GuruFocus
Ocular Therapeutix™ To Close Enrollment This Week for SOL-R, its - GuruFocus
Ocular Therapeutix™ To Close Enrollment This Week for - GlobeNewswire
Record-Breaking 555-Patient Trial Could Transform AMD Treatment with 12-Month Dosing Innovation - Stock Titan
Ocular Therapeutix chief scientific officer sells $21,712 in stock By Investing.com - Investing.com Canada
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $755,000 Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
D. E. Shaw & Co. Inc. Takes $268,000 Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix Executives Sell Shares to Cover Tax Obligations - TradingView
Ocular Therapeutix at Stifel 2025 Forum: Eyeing a Disruptive Future By Investing.com - Investing.com Canada
(OCUL) Trading Report - news.stocktradersdaily.com
BNP Paribas Financial Markets Acquires 39,599 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Ocular Therapeutix at BioConnect: Strategic Advances in Wet AMD Treatment By Investing.com - Investing.com Canada
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Holdings Boosted by Northern Trust Corp - Defense World
Ocular Therapeutix™ to Participate in Upcoming Investor Conferences - GlobeNewswire
Ocular Therapeutix CEO to Present at RBC, Mizuho, and Top Healthcare Conferences: Key Dates for Investors - Stock Titan
The Manufacturers Life Insurance Company Sells 2,399 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Transcript : Ocular Therapeutix, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 09 - marketscreener.com
Hsbc Holdings PLC Buys 5,853 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Tower Research Capital LLC TRC Has $76,000 Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
HC Wainwright Analysts Reduce Earnings Estimates for OCUL - Defense World
William Blair Brokers Decrease Earnings Estimates for OCUL - Defense World
Analysts Offer Predictions for OCUL FY2026 Earnings - Defense World
Ocular Therapeutix at The Citizens JMP Life Sciences Conference: Strategic Insights - Investing.com India
Bearish: Analysts Just Cut Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) Revenue and EPS estimates - simplywall.st
Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers - Yahoo Finance
Ocular Therapeutix (NASDAQ:OCUL) Trading Down 6.5% on Analyst Downgrade - Defense World
Analyst Expectations For Ocular Therapeutix's Future - Benzinga
Ocular Therapeutix (OCUL) Maintained as Buy by Needham, Price Ta - GuruFocus
Ocular Therapeutix First Quarter 2025 Earnings: Misses Expectations - Yahoo
Ocular Therapeutix Advances in Retinal Treatment Trials - TipRanks
Decoding Ocular Therapeutix Inc (OCUL): A Strategic SWOT Insight - GuruFocus
Ocular Therapeutix: Q1 Earnings Snapshot - MySA
Ocular Therapeutix sees cash runway into 2028 - TipRanks
Ocular Therapeutix (OCUL) Stock Drops 13% After Q1 Earnings - Benzinga
Ocular Therapeutix reports Q1 EPS (38c), consensus (28c) - TipRanks
Ocular Therapeutix Inc earnings missed by $0.09, revenue fell short of estimates - Investing.com Nigeria
OCUL's Financial Position: Cash Reserves Expected to Sustain Unt - GuruFocus
Ocular Therapeutix Inc (OCUL) Q1 2025 Earnings: EPS of $(0.38) M - GuruFocus
Raymond James maintains strong buy on Ocular Therapeutix stock By Investing.com - Investing.com Canada
Ocular Therapeutix Inc (OCUL) 財務データ
収益
当期純利益
現金流量
EPS
6.48%
大文字化:
|
ボリューム (24 時間):